EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules

Caroline M Godfrey, Ashley A Leech iD, Kevin C McGann iD, Jinyi Zhu iD, Hannah N Marmor, Sophia Pena, Lyndsey C Pickup, Fabien Maldonado, Evan C Osmundson, Stacie B Dusetzina, Eric L Grogan, Stephen A Deppen

PLOS One · 2026

DOI: 10.1371/journal.pone.0343492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Caroline M Godfrey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Cost-Benefit Analysis, Artificial Intelligence, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDA NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Artificial intelligence-based radiomic approaches have been shown to accurately evaluate indeterminate pulmonary nodules. With the expansion of lung cancer screening and utilization of computed tomography imaging, indeterminate pulmonary nodules requiring diagnostic evaluation are increasingly common. Accurate non-invasive characterization may reduce time to cancer diagnosis and decrease invasive procedures for benign disease, but the cost-effectiveness of AI-based methods has not been quantified. We sought to evaluate the cost-effectiveness of AI-assisted clinician evaluation compared to clinician evaluation alone for the cancer risk stratification of patients with indeterminate pulmonary nodules.

Methods

We constructed a decision model assuming guideline-based care from a payer perspective with a lifetime horizon. The base case is a 1.1 cm incidentally discovered IPN in a 60-year-old operative candidate in a clinical population with a 65% malignancy prevalence. Cost per life-year gained (LYG) was the primary outcome. We conducted deterministic sensitivity analyses on all parameters and performed a probabilistic sensitivity analysis. Given clinical variability of malignancy prevalence, we assessed the malignancy prevalence threshold at which utilization of AI would be cost-effective.

Results

AI-supported clinician risk stratification resulted in an increase of 0.03 life years compared to clinician alone. With a 65% malignancy prevalence, AI was cost-effective with an incremental cost-effectiveness ratio (ICER) of $4,485/LYG. When the malignancy prevalence was < 5%, the ICER for AI support exceeded a standard willingness-to-pay threshold of $100,000/LYG.

Conclusions

In clinical settings with a pre-test probability of malignancy exceeding 5%, AI-supported IPN risk stratification is cost-effective compared to clinician assessment alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Effectiveness AnalysisCost-Benefit AnalysisArtificial IntelligenceLung NeoplasmsSolitary Pulmonary NoduleMultiple Pulmonary NodulesHumansMiddle AgedRisk AssessmentTomography, X-Ray Computed

Autor:innen und Institutionen

  • Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
  • Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America.
  • Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
  • Optellum Ltd, Oxford, United Kingdom.
  • Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
  • Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.

ORCID-Profile: Ashley A Leech, Kevin C McGann, Jinyi Zhu

Förderung

  • NCI NIH HHS
  • NIDA NIH HHS
  • National Institutes of Health
  • National Institute on Drug Abuse

Zitieren

APA

Godfrey, C. M., Leech, A. A., McGann, K. C., Zhu, J., Marmor, H. N., Pena, S., Pickup, L. C., Maldonado, F., Osmundson, E. C., Dusetzina, S. B., Grogan, E. L., & Deppen, S. A. (2026). Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules. PLOS One. https://doi.org/10.1371/journal.pone.0343492

Vancouver

Godfrey CM, Leech AA, McGann KC, Zhu J, Marmor HN, Pena S, et al. Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules. PLOS One. 2026. doi:10.1371/journal.pone.0343492

BibTeX
@article{Godfrey2026,
  author = {Godfrey, Caroline M and Leech, Ashley A and McGann, Kevin C and Zhu, Jinyi and Marmor, Hannah N and Pena, Sophia and Pickup, Lyndsey C and Maldonado, Fabien and Osmundson, Evan C and Dusetzina, Stacie B and Grogan, Eric L and Deppen, Stephen A},
  title = {Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0343492}
}
Kostenlos starten →